Douglas Conrad

A Multidimensional Diagnostic Approach for Chronic Obstructive Pulmonary Disease

Early Evidence of Chronic Obstructive Pulmonary Disease Obscured by Race-Specific Prediction Equations

Race-Specific Spirometry Equations Do Not Improve Models of Dyspnea and Quantitative Chest CT Phenotypes

Use of the Spirometric “Fixed-Ratio” Underdiagnoses COPD in African-Americans in a Longitudinal Cohort Study

Safety and microbiological activity of phage therapy in persons with cystic fibrosis colonized with Pseudomonas aeruginosa: study protocol for a phase 1b/2, multicenter, randomized, double-blind, placebo-controlled trial

Long-term safety and efficacy of tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study

Longitudinal Association Between Muscle Loss and Mortality in Ever Smokers

Multi-Omics Study of Keystone Species in a Cystic Fibrosis Microbiome

High-Resolution Longitudinal Dynamics of the Cystic Fibrosis Sputum Microbiome and Metabolome through Antibiotic Therapy

COPDGene® 2019: Redefining the Diagnosis of Chronic Obstructive Pulmonary Disease

Optimizing sequencing protocols for leaderboard metagenomics by combining long and short reads

Niche partitioning of a pathogenic microbiome driven by chemical gradients

Three-Dimensional Microbiome and Metabolome Cartography of a Diseased Human Lung

Ecological networking of cystic fibrosis lung infections

A phase 3, multi-center, multinational, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of levofloxacin inhalation solution (APT-1026) in stable cystic fibrosis patients

Microbial, host and xenobiotic diversity in the cystic fibrosis sputum metabolome

A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients

Multidimensional Clinical Phenotyping of an Adult Cystic Fibrosis Patient Population

Breath gas metabolites and bacterial metagenomes from cystic fibrosis airways indicate active pH neutral 2,3-butanedione fermentation

Biogeochemical Forces Shape the Composition and Physiology of Polymicrobial Communities in the Cystic Fibrosis Lung

Mass spectral similarity for untargeted metabolomics data analysis of complex mixtures

Clinical Insights from Metagenomic Analysis of Sputum Samples from Patients with Cystic Fibrosis

Mechanistic Model of Rothia mucilaginosa Adaptation toward Persistence in the CF Lung, Based on a Genome Reconstructed from Metagenomic Data

WS17.6 Phase 3 trial of inhaled levofloxacin (Aeroquin™, MP-376, APT-1026) vs. tobramycin inhalation solution (TIS) in intensively treated CF patients over 6 months

Metagenomics and metatranscriptomics: Windows on CF-associated viral and microbial communities

β-Adrenergic Sweat Secretion as a Diagnostic Test for Cystic Fibrosis

Collaborative Research: Center for Health Management Research